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Abstract
Background: The extracellular matrix has a major effect upon the malignant properties of bladder
cancer cells both in vitro in 3-dimensional culture and in vivo. Comparing gene expression of several
bladder cancer cells lines grown under permissive and suppressive conditions in 3-dimensional
growth on cancer-derived and normal-derived basement membrane gels respectively and on plastic
in conventional tissue culture provides a model system for investigating the interaction of
malignancy and extracellular matrix. Understanding how the extracellular matrix affects the
phenotype of bladder cancer cells may provide important clues to identify new markers or targets
for therapy.
Methods: Five bladder cancer cell lines and one immortalized, but non-tumorigenic, urothelial line
were grown on Matrigel, a cancer-derived ECM, on SISgel, a normal-derived ECM, and on plastic,
where the only ECM is derived from the cells themselves. The transcriptomes were analyzed on
an array of 1186 well-annotated cancer derived cDNAs containing most of the major pathways for
malignancy. Hypervariable genes expressing more variability across cell lines than a set expressing
technical variability were analyzed further. Expression values were clustered, and to identify genes
most likely to represent biological factors, statistically over-represented ontologies and
transcriptional regulatory elements were identified.
Results: Approximately 400 of the 1186 total genes were expressed 2 SD above background.
Approximately 100 genes were hypervariable in cells grown on each ECM, but the pattern was
different in each case. A core of 20 were identified as hypervariable under all 3 growth conditions,
and 33 were hypervariable on both SISgel and Matrigel, but not on plastic. Clustering of the
hypervariable genes showed very different patterns for the same 6 cell types on the different ECM.
Even when loss of cell cycle regulation was identified, different genes were involved, depending on
the ECM. Under the most permissive conditions of growth where the malignant phenotype was
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fully expressed, activation of AKT was noted. TGFβ1 signaling played a major role in the response
of bladder cancer cells to ECM. Identification of TREs on genes that clustered together suggested
some clustering was driven by specific transcription factors.
Conclusion: The extracellular matrix on which cancer cells are grown has a major effect on gene
expression. A core of 20 malignancy-related genes were not affected by matrix, and 33 were
differentially expressed on 3-dimensional culture as opposed to plastic. Other than these genes, the
patterns of expression were very different in cells grown on SISgel than on Matrigel or even plastic,
supporting the hypothesis that growth of bladder cancer cells on normal matrix suppresses some
malignant functions. Unique underlying regulatory networks were driving gene expression and
could be identified by the approach outlined here.
Background
Bladder cancer has the fourth highest incidence in men
and seventh in women in the US [1]. Superficial papillary
bladder cancers, though they may grow very large, do not
invade and generally can be managed by excision. The
more aggressive invasive bladder cancers that develop de
novo have a five-year survival rate of 5% or less if metasta-
sis has occurred [2,3]. Although 85% of bladder cancers
first appear as superficial papillary carcinomas, up to two-
thirds of patients experience recurrence, with approxi-
mately 15–25% progressing to higher grade tumors [2,3].
Approximately half of the deaths from bladder cancer
result from progression. The extracellular matrix plays a
crucial role in the development and evolution of bladder
cancers [4-6]. The finding that specific genetic alterations
frequently associated with bladder cancer are detectable in
histologically normal urothelium of patients with bladder
cancer [7] suggests that the malignant phenotype can be
suppressed in vivo. This observation strongly suggests that
understanding how the extracellular matrix modulates the
phenotype of bladder cancer cells is highly relevant to
understanding the processes of recurrence and progres-
sion.
Models for investigating interactions between the extracel-
lular matrix (ECM) and bladder cancer cells using 3-
dimensional culture have shown the ECM plays a crucial
role in modulating the phenotype of bladder cancer cells
[4,5,8-10]. Previous studies in our laboratory show sup-
pression of the malignant phenotype when cells are cul-
tured on a normal ECM [9,10]. On Matrigel, which is
prepared from a cancer-modified ECM, bladder cancer
cells recapitulate their in vivo phenotype. In contrast,
when grown on SISgel, which is prepared from normal
basement membrane ECM, the tumorigenic cell lines lose
their invasiveness or ability to form papillary structures.
Instead, they form either multiple or single layers resem-
bling normal urothelium. By systematically varying both
malignancy in the form of the cell line and the ECM on
which they are grown, the interaction between these bio-
logical variables can be examined at the level of gene tran-
scription. In this study, expression of 1186 well-annotated
cancer-associated genes was measured on a cDNA array.
The study design involved 6 cell lines varying from non-
malignant to highly malignant grown on two ECM prepa-
rations and on plastic. Because practical considerations
limited the number of replicates to 2, the dataset was
inherently "noisy." We therefore developed statistically
valid, novel approaches to data analysis that can identify
biologically relevant patterns in a noisy dataset. Applica-
tion of these methods for the given dataset yielded clear
distinction in gene expression between different cell lines
and/or matrixes.
Methods
Cell culture
SV-HUC-1, TCCSUP, RT4 and J82 cells were obtained
from the American Type Culture Collection, Bethesda,
MD, which provided information allowing the cells to be
ranked by malignancy of the tumor of origin. The 253 J
and 253 JB-V cells were provided by Dr. Colin Dinney
[11]. The former is derived from a metastatic tumor, while
the latter is a highly metastatic variant cloned in Dr. Din-
ney's laboratory after 5 passages of 253 J cells in the blad-
der walls of nude mice. Although invasive and metastatic,
the tumor morphology is papillary. The ranking according
to malignancy from lowest to highest is: SV-HUC-1 (non-
malignant but immortalized), RT4 (low grade), 253 J
(high grade) 253 JB-V (high grade), J82 (high grade),
TCCSUP (high grade). Excepting the non-malignant SV-
HUC-1 cells and possibly the TCCSUP cells (see below),
all the cancer cell lines are transitional cell carcinomas
(TCC). Details of cell culture on Matrigel and SISgel have
been reported previously [9,10]. Culture on both matrices
plus plastic in which the proliferation rate is approxi-
mately the same in all 3 has been described previously
[12].
Array protocol
RNA was isolated from the cells growing in 3 dimensional
culture using the RNeasy kit (Qiagen) by adding 300 µl
lysis buffer to the culture well and pipeting up and down
to lyse the cells and dissolve the gel. The RNA was isolated
from the lysate using a QIAshredder spin column to com-BMC Cancer 2006, 6:12 http://www.biomedcentral.com/1471-2407/6/12
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plete homogenization followed by proteinase K digestion,
washing, DNase 1 treatment and elution from RNeasy
spin column. Yield of total RNA and the purity were
assessed by spectrophotometry. The yield was approxi-
mately 2.4 – 6 µg RNA per culture in 30 µl. First strand
synthesis was carried out at 42°C for 1 h with reagents
supplied by Clontech as part of the SMART II kit, except
that Superscript II (Invitrogen) reverse transcriptase was
substituted. The SMART II oligonucleotide was included
to capture full length cDNA at the 5'end and to permit a
proportional 2,000 – 5,000 fold amplification [13].
Labeled probe was produced from an aliquot of the
amplified probe with Klenow fragment and 32P-labeled
nucleotide. After probe purification, 15 × 106 cpm of
probe was hybridized in duplicate to the Clontech
Human Cancer 1.2 array on nylon following the protocol
provided by the company. The Clontech Human Cancer
1.2 array is a focused array consisting of 1186 well-anno-
tated cancer-associated genes. The results were visualized
by exposing a phosphoimager screen overnight and then
reading with the Packard Cyclone phosphoimager and
Optiquant software.
Data normalization
Data were normalized as described in detail elsewhere
[14]. In brief, the normalization method relies on a
number of low expression genes to provide an estimate of
non-specific binding. This information is then used to
perform a Z transformation on the data. Once normal-
ized, the data are "unbiased" through robust linear regres-
sion to allow comparisons across different arrays. Fitted
data are then used to find a homoscedastic group of gene
variances that will be used as an internal standard of
measurement noise [15]. Expressed genes (expression lev-
els 2 standard deviations above the mean of the back-
ground) were noted, anti-log transformed, and used for
subsequent analysis. This filtering step minimizes false
positives, though at the cost of the low-expression genes,
which are measured with low precision anyway.
Hypervariable gene identification
The logic of this step is that the variability within a dataset
consists of both experimental error and variability intro-
duced by the biological variables of interest. Moreover,
while genes that do not vary significantly may be repre-
senting ongoing physiologic processes, they are unlikely
to be correlated with malignancy or the effect of ECM
since they do not change with either of those variables.
Dozmorov, et al. [14] presented a method to identify the
subset of genes that most likely represent experimental
variability. Those genes with statistically significant varia-
bility greater than this subset represent the hypervariable
genes that are most likely to represent the action of bio-
logical variables. Thus, in this study any gene that showed
variable expression across cell lines exceeding the estimate
of technical variability would be considered hypervaria-
ble. In order to reduce noise in the dataset and to insure
adequate statistical power, the list was filtered to remove
genes that were not expressed 2 SD above background in
at least 4 of 6 cell lines for growth on each ECM condition.
This filtering reduced the 1186 genes to roughly 400 for
each matrix, with about 100 being identified as hypervar-
iable.
Correlational clustering
The expression values of the hypervariable genes were
clustered using Gene Cluster from M. B. Eisen [16]. The
data were log-transformed, arrays and genes were median-
centered and the transformed dataset was hierarchically
clustered using uncentered correlational clustering. The
results were displayed with TreeView, also from M. B.
Eisen.
Identification of significantly over-represented gene 
ontologies
The annotations of the gene lists and their individual
ontologies were first updated using the publicly available
on-line tool DAVID EASE [17]. The null hypothesis that
the clusters identified arose by chance was tested by deter-
mining whether any gene ontologies were over-repre-
sented above chance using the Gene Ontology Tree
Machine (GOTM) [18,19].
Pathway analysis
Biologically relevant networks were assembled from iden-
tified clusters and groups of common genes by using Inge-
nuity Pathways Analysis (IPA). This web-delivered
application [20] enables the visualization and analysis of
direct and indirect interactions among genes. Selected
data sets were uploaded as Excel files containing GenBank
Accession numbers for genes of interest. Each gene identi-
fier was mapped to its corresponding gene object in the
Ingenuity Pathways Knowledge Base. Genes were not
weighted by expression levels, and biological networks
were built on this assumption.
Transcriptional regulatory element (TRE) analysis
One strategy for analyzing the significance of gene clusters
identified by correlational clustering is based upon the
assumption that co-expressed genes are likely to share
common regulatory motifs [21]. This analysis was per-
formed using the web-based program PAINT [22,23]. The
results depend upon the reference chosen thereby reflect-
ing Bayesian probability. If the entire genome is selected
as the reference, the results will emphasize TREs common
to bladder cells and would therefore identify tissue-spe-
cific TREs. Alternately, if the list of all genes expressed on
a given matrix is selected as the reference, then the results
should be enriched in those TREs responsible for the clus-
tering rather than tissue-specific promoters. If the refer-BMC Cancer 2006, 6:12 http://www.biomedcentral.com/1471-2407/6/12
Page 4 of 12
(page number not for citation purposes)
ence is the list of hypervariable genes, then significance of
the partitioning of the hypervariable genes by clusters and
TREs is identified. The PAINT analysis was performed
against each of the indicated references, but only the ref-
erence against all hypervariable genes was reported.
Results
Identification of hypervariable genes
Cells grown on plastic expressed 422/1186 genes in at
least 4/6 cell lines. On SISgel and Matrigel the correspond-
ing numbers were 411 and 409 respectively. Overall, 371
genes were expressed in at least 12/18 conditions (6 cell
lines grown under 3 conditions). The lists were further fil-
tered by identifying the set of hypervariable genes. This
yielded lists of approximately 100 genes from each set of
experiments on an individual matrix. The results are
expressed by a Venn diagram (Figure 1). The full gene lists
and descriptions are available [see Additional file 1]. Fig-
ure 1 shows roughly half of each set of hypervariable
genes was expressed uniquely on one ECM. Only 20 genes
were expressed in common on all three ECMs (Table 1),
and 33 genes were showed hypervariable expression on
both SISgel and Matrigel (Table 2), whereas 15 and 7 were
hypervariable on plastic and either SISgel and Matrigel,
respectively. Full ontologic descriptions of these 20 and
33 genes are presented [see Additional file 2, Additional
file 3].
Clustering of hypervariable genes
Hierarchical clustering by correlation of gene expression is
presented in Figure 2. Gene expression from cells grown
on Matrigel, where the bladder cancer cells are capable of
fully expressing their malignant phenotype, clustered into
seven main correlational clusters (M1–M7) (Figure 2A).
The correlations in expression in some of the clusters,
such as M2 and M4, are very high (>0.8). The clustering
tended to be driven by expression in individual cell types
rather than groups, such as cells derived from low-grade
tumors. The driving signature (the cell line that drives
organization of a cluster), and the over-represented ontol-
ogies are summarized in Table 3. The full statistical infor-
mation as well as gene names associated with individual
ontologies are listed [see Additional file 4].
Analysis of biological pathways
Ingenuity Pathways Analysis identified specific biological
pathways behind each given cluster on different ECMs.
Cluster M4, containing 29 genes underexpressed in non-
malignant HUC cells, showed two non-overlapping net-
works of 16 and 10 genes, respectively. The first pathway
involved TGFβ1 signaling. The second pathway involved
p53, IFNG and Fos-responsive genes. The details of the
genes identified and their functions are listed in Table 4.
The pathways showing the interconnections among the
genes are shown [see Additional file 6]. Cluster P7, which
consists of 16 genes underexpressed in HUC cells, showed
a network of 12 genes involving TGFβ1 and p53 as central
players (Table 4).
Pathway analysis of the 20 genes hypervariable under all
growth conditions contained a network of 18 genes
involved in TGFβ1 signaling. Contained in the 33 genes
that were hypervariable on both ECM preparations but
not on plastic were two networks of 15 and 11 genes
respectively. The 15 gene network consisted of genes
involved in TGFβ1 signaling, the AKT1 survival network,
CDKN1A cell cycle regulation and IL1β signaling. The 11
gene network consisted of a c-Myc response network and
EGF signaling. These genes are also listed in Table 4 and
the pathways are presented [see Additional file 6].
Transcriptional regulatory element (TRE) analysis of 
correlational clusters
TRE analysis was used to determine whether the correla-
tion clustering could be interpreted in terms of the actions
of networks of transcription factors. Figure 3 shows the
results of analysis of TREs with the PAINT program
according to the clusters defined by the hierarchical clus-
tering. Each cluster expressed a pattern that was distinct
from other clusters confirming the results of hierarchical
clustering. This can be seen on full TREs maps [see Addi-
tional file 5] or, more clearly, on filtered maps, see Figure
3.
Venn diagram of hypervariable genes expressed on different  matrixes Figure 1
Venn diagram of hypervariable genes expressed on dif-
ferent matrixes. Each circle contains number of hypervaria-
ble genes unique and/or common for different matrixes. The 
size of circles does not represent relative number of genes in 
each group.BMC Cancer 2006, 6:12 http://www.biomedcentral.com/1471-2407/6/12
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Discussion
In this study we sought to identify genes that modulate
the malignant phenotype of bladder cancer. The experi-
mental design made genes modulating the phenotype
hypervariable as six different cell lines with different
inherent malignancies were grown on plastic and two dif-
ferent extracellular matrices. Because varying the substrate
on which the cells are grown changes the malignant phe-
notype, genes that modulate the phenotype were there-
fore brought to the fore. Our approach for analysis of this
noisy dataset first consisted of identifying the subset of
hypervariable genes because this subset will contain the
set of genes encapsulating the relevant biological effect
[14]. This step is designed to minimize false negatives for
further in silico analysis. The subsequent steps sought to
generate testable hypotheses with minimal false positives.
By finding gene ontologies, pathways and TRE motifs that
were significantly enriched within individual clusters,
genes that potentially functioned together in pathways
were identified. Because microarray studies are weighted
toward high expression genes, these approaches, particu-
larly pathways and TRE analysis can identify effects due to
low expression genes such as transcription factors whose
expression may be too low to be detected with the micro-
array. Because these determinations are made with refer-
ence to statistical probability, the only step in the analysis
Table 1: Hypervariable genes commonly expressed between Matrigel, Plastic and SISgel
GENBANK SYMBOL GENENAME
U13696 PMS2 PMS2 postmeiotic segregation increased 2 (S. cerevisiae)
M68520 CDK2 cyclin-dependent kinase 2
X80692 MAPK6 mitogen-activated protein kinase 6
X76104 DAPK1 death-associated protein kinase 1
S85655 PHB prohibitin
AF000546 P2RY5 purinergic receptor P2Y, G-protein coupled, 5
M97934 STAT2 signal transducer and activator of transcription 2, 113 kDa
X02851 IL1A interleukin 1, alpha
X86779 FASTK FAST kinase
U56390 CASP9 caspase 9, apoptosis-related cysteine protease
U60520 CASP8 caspase 8, apoptosis-related cysteine protease
X57766 MMP11 matrix metalloproteinase 11 (stromelysin 3)
M55172 AGC1 aggrecan 1 (chondroitin sulfate proteoglycan 1, large aggregating proteoglycan, antigen identified by monoclonal 
antibody A0122)
X03168 VTN vitronectin (serum spreading factor, somatomedin B, complement S-protein)
U65410 MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast)
X06374 PDGFA platelet-derived growth factor alpha polypeptide
L27943 CDA cytidine deaminase
X03124 TIMP1 tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)
A14844 IL2 interleukin 2
M26326 KRT18 keratin 18
Table 4: Genes and Functions in Ingenuity Pathways
Cluster/Network Genes Top Functions
Matrigel_4/1 AKT1, CLK2, CSE1L, DAPK1, FN1, G22P1, KRT7, KRT8, 
KRT18, PARP1, RAC1, TGFB1, TIMP2, TNFRSF1B, XRCC1, 
XRCC5
DNA replication, Recombination and Repair; 
Cell Death; Neurological Disease
Matrigel_4/2 BAG1, CASP10, COPS5, CRADD, EIF2AK2, FASTIK, HNRPK, 
TP53BP1, TRAF6, XPO1
Cell Cycle; Connective Tissue Disorders; 
Inflammatory Disease
Plastic_7/1 BIRC5, CTPS, DAP3, GADP, GLIPR1, HLA-DMA, MMP7, 
MMP11, MT3, RRM2, TIMP1, TXNRD1
Cancer; Cell Death; Respiratory Disease
Mat-Pla-SIS Common Genes/1 AGC1, CASP8, CASP9, CDK2, DAPK1, FASTK, IL2, IL1A, 
KRT18, MAD2L1, MAPK6, MMP11, PDGFA, PHB, PMS2, 
STAT2, TIMP1, VNT
Cell Death; Cancer; Cell Cycle
Mat-SIS Common Genes/1 ADCYAP1R1, AKT1, CDC2, CDKN1A, CDKN1C, HLA-C, 
IL10, IL1B, ITGA7, KRT8, PDGFB, PMS1, SERPINB2, SPINT2, 
TGFB1
Cancer; Cell Morphology; Cell Cycle
Mat-SIS Common Genes/2 CASP10, CBX5, CTNN1, DAB2, ELF1, G22P1, HNRPK, OAS1, 
RALB, TIMP2, XRCC5
Cancer; Cell Death; Reproductive System 
DiseaseBMC Cancer 2006, 6:12 http://www.biomedcentral.com/1471-2407/6/12
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process that does not contain a quantitative estimate of
statistical significance is the clustering.
Except for clusters M4 and P7 the driving force for cluster-
ing appeared to represent the behavior of individual cell
lines rather than overall malignancy. However, these two
clusters identify genes generally expressed at higher levels
in the malignant cells than in the HUC cells. Of particular
interest is the apparent activation of pro-survival AKT1
signaling in the malignant cells on Matrigel [see Addi-
tional file 6]. Likewise, the receptor for TGFβ1 was
expressed at high levels on all the malignant cells on
Matrigel (Figure 2), which supports the finding of TGFβ1
signaling genes in several clusters by the pathway analysis
tool. Other ontologies in these two clusters clearly showed
connections to cancer and apoptosis. The gene ontology
and pathway analysis agreed in identifying the p53 signal-
ing and TGFβ1 pathways within these clusters. While the
mechanisms identified as operating only within a single
cell line are probably less interesting than those operating
in several, identification of a range of behaviors in bladder
cancers could become useful if pathway-specific drugs are
developed.
Some 20 genes were identified as being hypervariable,
regardless the substrate. These represent a group of genes
that are not modulated by the ECM but are differentially
expressed among the different cell lines. Examples include
Prohibitin (PHB), a survival gene, which is entirely
matrix-independent. The connection with AKT1 survival
pathway is clear. In bladder cancer, activation of AKT1-
mediated survival has only been shown in TCCSUP cells
in culture [24]. AKT1 can cause resistance to therapy in
other cancers [25]. Interestingly, genes coding for two
polysaccharide-binding proteins were also present. That
these two would be differentially expressed by different
cell types growing on polysaccharide-containing gels and
the minimal endogenous matrix secreted by cells growing
Table 2: Hypervariable genes commonly expressed between Matrigel and SISgel
GENBA
NK
SYMBOL GENENAME
U13695 PMS1 PMS1 postmeiotic segregation increased 1 (S. cerevisiae)
M63167 AKT1 v-akt murine thymoma viral oncogene homolog 1
M11810 OAS1 2',5'-oligoadenylate synthetase 1, 40/46 kDa
X05360 CDC2 cell division cycle 2, G1 to S and G2 to M
M32865 G22P1 thyroid autoantigen 70 kDa (Ku antigen)
M57627 IL10 interleukin 10
S74678 HNRPK heterogeneous nuclear ribonucleoprotein K
U69127 FUBP3 far upstream element (FUSE) binding protein 3
D17516 ADCYAP1R1 adenylate cyclase activating polypeptide 1 (pituitary) receptor type I
U22398 CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2)
L25081 ARHC ras homolog gene family, member C
M35416 RALB v-ral simian leukemia viral oncogene homolog B (ras related; GTP binding protein)
M11886 HLA-C major histocompatibility complex, class I, C
X74295 MGC17301 hypothetical protein MGC17301
X02812 TGFB1 transforming growth factor, beta 1 (Camurati-Engelmann disease)
M18082 SERPINB2 serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2
K02770 IL1B interleukin 1, beta
U60519 CASP10 caspase 10, apoptosis-related cysteine protease
D13866 CTNNA1 catenin (cadherin-associated protein), alpha 1, 102 kDa
U09579 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1)
U78095 SPINT2 serine protease inhibitor, Kunitz type, 2
U53446 DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)
X02811 PDGFB platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog)
X91940 WNT8B wingless-type MMTV integration site family, member 8B
X74295 ITGA7 integrin, alpha 7
M30938 XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining; Ku 
autoantigen, 80 kDa)
L07515 CBX5 chromobox homolog 5 (HP1 alpha homolog, Drosophila)
M34225 KRT8 keratin 8
J05593 TIMP2 tissue inhibitor of metalloproteinase 2
D83597 LY64 lymphocyte antigen 64 homolog, radioprotective 105 kDa (mouse)
M82882 ELF1 E74-like factor 1 (ets domain transcription factor)
J00209 IFNA10 interferon, alpha 10
U09825 TRIM26 tripartite motif-containing 26BMC Cancer 2006, 6:12 http://www.biomedcentral.com/1471-2407/6/12
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Hierarchical clustering of hypervariable genes across different cell lines on different matrixes Figure 2
Hierarchical clustering of hypervariable genes across different cell lines on different matrixes. Hierarchical clustering of 
genes up- (red color) or downregulated (green color) on the given 6 cell lines. A, B and C show clustering of genes expressed 
on Matrigel, Plastic and SISgel, respectively. Colored bars outline individual clusters used for subsequent analysis.BMC Cancer 2006, 6:12 http://www.biomedcentral.com/1471-2407/6/12
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on plastic is consistent with the role of these molecules in
differentiation and growth [26]. Additionally, 33 genes
were identified as being hypervariable on both Matrigel
and SISgel, in spite of the suppression of many features of
the malignant phenotype on the latter. These genes prob-
ably represent a "core" set of cancer genes. Ontologies for
this cluster of genes were cancer, cell morphology and cell
cycle networks. Pathway analysis showed fifteen of these
genes functioned in TGFβ1 signaling, which is a potent
regulator of extracellular matrix production and prolifera-
tion [27]. An important role for TGFβ1 in bladder cancer
has been proposed [28]. Eleven of these 33 genes are inter-
connected within the MYC network. Deregulation of MYC
genes is associated with several malignancies [29].
Although the ECM can have major effects on the biology
of individual cancers, a core of oncogenes involved in the
p53 and MYC networks is unaffected. Interestingly, a set
of signature genes for the suppression of the malignant
phenotype by SISgel was not observed. Either the correct
probes are not on the array, or each cell type respond
uniquely to a changing matrix. Previous results showed
this response was not due to integrin signaling [9] as has
been reported by Weaver, et. al [30] to govern phenotypic
reversion of glandular breast cancers.
The TRE analysis confirmed the uniqueness of the cluster-
ing and suggests that a limited set of TREs may be driving
gene expression in this study. Notable is Hand1, which
appears in most of the genes. This gene has been identi-
fied as playing a role in heart development [31], but the
abundance in these genes that are expressed in bladder
suggests it may also act as a bladder-specific factor. Several
genes overexpressed in malignant cell lines in cluster M4
carried the E2F TRE. The corresponding transcription fac-
tor has been shown to promote cell growth in common
human carcinomas [32] and to be dependent on the p53
pathway [32,33] supporting its role in upregulating the
cluster in cancer cells. A different set of TREs was identi-
fied in Cluster P7. An estrogen receptor (ER) and myo-
genin (MYOG) were separately associated within P7. This
combination suggests loss of epithelial differentiation.
Bladder cancer cells were earlier demonstrated to contain
both functional androgen and estrogen receptors without
regard to the sex of the donor [34,35] while myogenin was
primary expressed in rhabdomyosarcomas [36,37]. Iden-
tification of myogenin expression in bladder cancer cell
lines is novel, and further research will be needed to deter-
mine if this transcription factor is actually active.
Comparisons to other microarray studies are, in general,
less informative because of wide differences among array
Table 3: Driving signatures and ontologies of gene clusters on different matrixes
Cluster Driving signature Ontology
Matrigel_1 J82 underexpressed negative regulation of biological process
Matrigel_2 JP underexpressed mRNA processing
Matrigel_3 HUC & JB overexpressed mismatch repair; transcription factor activity
Matrigel_4 HUC underexpressed anti-apoptosis; induction of apoptosis by extracellular signals; protein binding; protein serine/
threonine kinase activity
Matrigel_5 JB underexpressed regulation of cyclin dependent protein kinase activity; mitotic control; negative regulation of cell 
proliferation
Matrigel_6 JB & J82 underexpressed
Matrigel_7 J82 & JP overexpressed regulation of cyclin dependent protein kinase activity; anti-apoptosis; negative regulation of cell 
proliferation; positive regulation of cell proliferation; extracellular space
Plastic_1 JP underexpressed induction of apoptosis
Plastic_2 JP underexpressed
RT4 overexpressed
immune response
Plastic_3 TCCSUP & J82 overexpressed negative regulation of cell cycle
Plastic_4 TCCSUP underexpressed protein kinase cascade; meiotic recombination; cell cycle arrest; anti-apoptosis; induction of 
apoptosis by extracellular signals; protein ubiquitination; nucleotide-excision repair; protein binding; 
nucleus
Plastic_5 mitotic cell cycle; chromosome
Plastic_6 J82 underexpressed cell cycle arrest; nucleus
Plastic_7 HUC underexpressed negative regulation of cellular process; antioxidant activity; extracellular matrix
SISgel_1 J82 & JP overexpressed cell cycle; induction of apoptosis; extracellular matrix
SISgel_2 HUC underexpressed
J82 overexpressed
regulation of cell cycle; negative regulation of cell proliferation; inflammatory response
SISgel_3 JB underexpressed induction of apoptosis by extracellular signals; DNA replication; purine nucleotide biosynthesis; ligase 
activity, forming carbon-nitrogen bonds; cytoskeleton
SISgel_4 JB overexpressed
SISgel_5 RT4 underexpressed negative regulation of cell cycle
SISgel_6 J82 underexpressed cell division; protein complex assemblyBMC Cancer 2006, 6:12 http://www.biomedcentral.com/1471-2407/6/12
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Filtered maps of TREs on gene clusters of hypervariable genes identified in cells growing on different matrixes Figure 3
Filtered maps of TREs on gene clusters of hypervariable genes identified in cells growing on different matrixes. 
A, B and C show significantly significantly overrepresented (p < 0.05) TREs from cells grown on Matrigel, Plastic and SISgel, 
respectively. Colored bars represent individual gene clusters. The TREs and the transcription factors that bind to them (linked 
to Enterz Gene) are CCAAT/NFYC; CP2/TFCP2; CREB/CREBP; CRE-BP1/ATF2; E2F/E2F2; Elk-1/ELK1; ER/ESR1; GATA-3/
GATA-3; Hand1/HAND1; HFH-3/FOXI1; HNF-1/TCF1; HNF-3/FOXA1; myogenin/MYOG; Oct-1/POU2F1; v-Myb/MYB; 
XFD-3/FOXA1.BMC Cancer 2006, 6:12 http://www.biomedcentral.com/1471-2407/6/12
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technologies [38] and criteria to identify "significant"
genes. Nonetheless the composition of Cluster M4, which
is comprised of genes that are under-expressed in HUC
cells in comparison to all the cancer cells, shows 3 of the
28 genes in the cluster corresponded to 3 of the 29 genes
identified as being diagnostic for TCC in patient samples
[39]. This association suggests this cluster might provide
additional diagnostic genes which is strongly supported
by the finding of the p53-responsive gene network. In
addition, although the comparison was made difficult by
a lack of accession numbers or universal gene symbols,
considerable correspondence between the 32 genes iden-
tified as hypervariable in 3-dimensional growth was
noted with the set of genes reported to differentially
expressed between superficial and invasive TCC [40].
Conclusion
The extracellular matrix on which cancer cells are grown
has a major effect on gene expression. A core of 20 malig-
nancy-related genes were not affected by matrix, and 33
were differentially expressed on 3-dimensional culture as
opposed to plastic. Activation of the AKT1 survival path-
way on Matrigel suggests this pathway could be relevant to
clinical bladder cancer. The TGFβ1 signaling pathway
plays an important role in the expression of the malignant
phenotype. The p53 response network is confirmed to
play a central role, as does c-MYC signaling. Evidence sug-
gests the E2F TF drives some malignancy-related genes,
with several other TFs being implicated as well. The iden-
tified pathways may provide new targets for detection and
treatment therapies.
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